CYTHW | Cyclo Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.1800 - 0.2499
52 Week Range	0.0500 - 0.3700
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	1,200
Average Volume	857
Shares Outstanding	82,861,280
Market Cap	20,707,054
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
IPO Date	2020-12-18

Valuation
Profitability
Growth
Health
P/E Ratio	N/A
Forward P/E Ratio	N/A
EPS	N/A
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	8
Country	USA
Website	CYTHW

Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. Its product pipeline include Trappsol Cyclo, which treats Neimann-Pick Type C disease and Alzheimer's disease. The company was founded by Charles E. Rick Strattan on August 9, 1990 and is headquartered in Gainesville, FL.

CYTHW's peers: AMPGW

*Chart delayed

Analyzing fundamentals for CYTHW we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is poor, Growth is bad and Health is frighteningly weak. For more detailed analysis please see CYTHW Fundamentals page.

Watching at CYTHW technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on CYTHW Technicals page.